RNS Number : 4004H
Shield Therapeutics PLC
31 July 2019

Shield Therapeutics plc
("Shield" or the "Group")

Notice of results

London, UK, 31 July 2019: Shield Therapeutics plc (LSE: STX), a commercial stage, pharmaceutical company with a focus on addressing iron deficiency, announces it will release its interim results for the six months ended 30 June on Wednesday 7 August 2019.

Analyst briefing
A briefing for analysts will take place at 9.30am on Wednesday 7 August 2019. If you would like to register, please contact Walbrook PR on 020 7933 8780 or email shield@walbrookpr.com

For further information please contact:

Shield Therapeutics plc www.shieldtherapeutics.com
Carl Sterritt, Chief Executive Officer +44 (0)20 7186 8500
Tim Watts, Chief Financial Officer

Nominated Advisor and Broker
Peel Hunt LLP
James Steel/Dr Christopher Golden +44 (0)20 7418 8900

Joint Broker
finnCap Ltd +44 (0)20 7220 0500
Geoff Nash/Matt Radley/Alice Lane

Financial PR & IR Advisor
Walbrook PR +44 (0)20 7933 8780
or shield@walbrookpr.com
Paul McManus / Lianne Cawthorne +44 (0)7980 541 893 / +44 (0)7584 391 303

About Shield Therapeutics plc

Shield is a de-risked, commercial stage, specialty pharmaceutical company delivering innovative pharmaceuticals to address patients' unmet medical needs. The Company's clear purpose is to help its patients become people again, by enabling them to enjoy the things that make the difference in their everyday lives. The Group has a marketed product, Feraccru® / Accrufer®, for the treatment of iron deficiency in adults which has exclusive IP rights until the mid-2030s. Feraccru® / Accrufer®, is approved by the FDA, EMA and Swiss Medic for the treatment of iron deficiency in adults and is commercialised in the European Union by Norgine BV, with a US commercialisation partner currently being selected. For more information please visit www.shieldtherapeutics.com.

About Feraccru®/ Accrufer®

Feraccru®/ Accrufer® is a novel, stable, non-salt based oral treatment for adults with iron deficiency with or that has been shown to be an efficacious and well-tolerated therapy in a range of controlled phase 3 trials. Following the recently announced positive results of the Phase IIIb AEGIS-H2H study in which Feraccru® demonstrated it was non-inferior to intravenously-administered Ferinject® at delivering improvements in haemoglobin levels without requiring hospital-based administration, Feraccru®/ Accrufer® offers a compelling alternative to IV Iron for those patients that cannot tolerate salt-based oral iron therapies and wish to avoid the complexities of infusion-based therapies.

When salt-based oral iron therapies are ingested they can cause a range of mild-to-severe gastrointestinal tract (GI) adverse events, including nausea, bloating and constipation. These lead to poor tolerability, reduced patient compliance and ultimately treatment failure. Feraccru®/ Accrufer® is not an iron salt; iron can be absorbed from the ferric maltol molecule and, as a result, it does not routinely cause the same treatment-limiting intolerance issues.

Prior to Feraccru®/ Accrufer®, IV iron therapies were the only realistic alternative treatment option for patients intolerant of or unwilling to take salt-based oral iron therapies. However, use of such an invasive, costly, inconvenient and complex to administer treatment option, which is associated with potentially life-threatening and spontaneous hypersensitivity reactions, means there remains a clear unmet medical need for patients with iron deficiency to have access to an effective therapy like Feraccru®/ Accrufer® that is well tolerated, convenient and does not require hospital-based administration.

About Iron Deficiency

The WHO state that iron deficiency is the most common and widespread nutritional disorder in the world. As well as affecting a large number of children and women in non-industrialized countries, it is the only nutrient deficiency which is also significantly prevalent in virtually all industrialized nations. There are no current global figures for iron deficiency, but using anaemia as an indirect indicator it can be estimated that most preschool children and pregnant women in non-industrialized countries, and at least 30-40% in industrialized countries, are iron deficient.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NORBBGDRGDXBGCB